Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q3 FY20 results · Oct–Dec 2019
Gufic Biosciences reported revenue from operations of ₹97.74 crore (up 11.5% from Q3 FY19) and net profit of ₹7.02 crore (up 19.4% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a standalone basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 97.74 | 87.65 | +11.5% | 86.03 | +13.6% |
| Other income | 3.06 | 0.23 | 14x | 1.61 | +89.8% |
| Total income | 100.80 | 87.88 | +14.7% | 87.64 | +15.0% |
| Profit before tax | 9.42 | 8.79 | +7.2% | 5.65 | +66.7% |
| Net profit for the period | 7.02 | 5.88 | +19.4% | 4.30 | +63.1% |
| EPS, basic (₹) | 0.90 | 0.76 | +18.4% | 0.55 | +63.6% |
| Net margin (%) | 7.2 | 6.7 | 5.0 |
Standalone
- Filed with BSE
- 14 Feb 2020, 19:45 IST
- Board meeting
- 13 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE